ArticleThe Journal of clinical investigation2011
CD98 expression modulates intestinal homeostasis, inflammation, and colitis-associated cancer in mice.
Article in The Journal of clinical investigation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 127 citations in OpenAlex.
- Intestinal amino acid metabolic response and its roles in inflammatory bowel disease.Cell communication and signaling : CCS · 2025Review
- Engineered Metal-Organic Frameworks for Targeted CRISPR/Cas9 Gene Editing.ACS pharmacology & translational science · 2025Review
- The Construction Strategy of Curcumin Nanomedicine Delivery System and Its Application in the Treatment of Ulcerative Colitis.International journal of nanomedicine · 2025Review
- Mesoporous nanomaterial-based smart nanoplatforms for precise therapies of ulcerative colitis: Strategies and challenges.Theranostics · 2025Review
- Nano-drug delivery systems (NDDS) in metabolic dysfunction-associated steatotic liver disease (MASLD): current status, prospects and challenges.Frontiers in pharmacology · 2024Review
- Macrophage-Derived Extracellular Vesicles-Coated Palladium Nanoformulations Modulate Inflammatory and Immune Homeostasis for Targeting Therapy of Ulcerative Colitis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Plant-derived exosomal nanoparticles: potential therapeutic for inflammatory bowel disease.Nanoscale advances · 2023Review
- CD73-Positive Cell Spheroid Transplantation Attenuates Colonic Atrophy.Pharmaceutics · 2023Article
- Transporter-Mediated Drug Delivery.Molecules (Basel, Switzerland) · 2023Review
- CD98 heavy chain as a prognostic biomarker and target for cancer treatment.Frontiers in oncology · 2023Review
- Mucus-Penetrating Silk Fibroin-Based Nanotherapeutics for Efficient Treatment of Ulcerative Colitis.Biomolecules · 2022Article
- CD98hc has a pivotal role in maintaining the immuno-barrier integrity of basal layer cells in esophageal epithelium.Cancer cell international · 2022Article
- Expression of CD98hc in Pancreatic Cancer and Its Role in Cancer Cell Behavior.Journal of Cancer · 2022Article
- CD98-induced CD147 signaling stabilizes the Foxp3 protein to maintain tissue homeostasis.Cellular & molecular immunology · 2021Article
- Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: Opportunities and emerging strategies.Acta pharmaceutica Sinica. B · 2021Review
- Tsc1 regulates tight junction independent of mTORC1.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Dietary Methionine Supplementation Exacerbates Gastrointestinal Toxicity in a Mouse Model of Abdominal Irradiation.International journal of radiation oncology, biology, physics · 2021Article
- Current Strategies and Potential Prospects of Nanomedicine-Mediated Therapy in Inflammatory Bowel Disease.International journal of nanomedicine · 2021Review
- Natural Product-Based Nanomedicine in Treatment of Inflammatory Bowel Disease.International journal of molecular sciences · 2020Review
- Loss of the branched-chain amino acid transporter CD98hc alters the development of colonic macrophages in mice.Communications biology · 2020Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 3 countries.
Funding
Abstract
Expression of the transmembrane glycoprotein CD98 (encoded by SLC3A2) is increased in intestinal inflammatory conditions, such as inflammatory bowel disease (IBD), and in various carcinomas, yet its pathogenetic role remains unknown. By generating gain- and loss-of-function mouse models with genetically manipulated CD98 expression specifically in intestinal epithelial cells (IECs), we explored the role of CD98 in intestinal homeostasis, inflammation, and colitis-associated tumorigenesis. IEC-specific CD98 overexpression induced gut homeostatic defects and increased inflammatory responses to DSS-induced colitis, promoting colitis-associated tumorigenesis in mice. Further analysis indicated that the ability of IEC-specific CD98 overexpression to induce tumorigenesis was linked to its capacity to induce barrier dysfunction and to stimulate cell proliferation and production of proinflammatory mediators. To validate these results, we constructed mice carrying conditional floxed Slc3a2 alleles and crossed them with Villin-Cre mice such that CD98 was downregulated only in IECs. These mice exhibited attenuated inflammatory responses and resistance to both DSS-induced colitis and colitis-associated tumorigenesis. Together, our data show that intestinal CD98 expression has a crucial role in controlling homeostatic and innate immune responses in the gut. Modulation of CD98 expression in IECs therefore represents a promising therapeutic strategy for the treatment and prevention of inflammatory intestinal diseases, such as IBD and colitis-associated cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.